Evidence map›Paper›PMID 41835811›Full record

ArticleEuropean heart journal open2026

'Ablate and pace' reduces mortality in heart failure patients with atrial fibrillation: an updated meta-analysis.

Christian Lewinter, John G F Cleland, Eslem Sögütlü, Torsten Holm Nielsen, Hannes Hagström, Lars Køber, Martin LeWinter, Robert Edfors, Cecilia Linde, Frieder Braunschweig

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Christian LewinterHeart Centre, Karolinska University Hospital, Eugeniavägen 3, SE-171 76 Stockholm, Sweden.ORCID https://orcid.org/0000-0002-7267-2178
John G F ClelandSchool of Cardiovascular and Metabolic Health, University of Glasgow, University Avenue, G12 8TA Glasgow, UK.
Eslem SögütlüKarolinska Institutet, Nobels väg 6, SE-171 77 Stockholm, Sweden.
Torsten Holm NielsenDanish Medicines Agency, Axel Heides Gade 1, DK-2300 Copenhagen S, Denmark.
Hannes HagströmKarolinska Institutet, Nobels väg 6, SE-171 77 Stockholm, Sweden.ORCID https://orcid.org/0000-0002-8474-1759
Lars KøberHeart Centre, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark.ORCID https://orcid.org/0000-0002-6635-1466
Martin LeWinterDivision of Cardiovascular Medicine, White River Junction Veterans Affairs Medical Center, 215 North Main Street, White River Junction, VT 05009, USA.
Robert EdforsKarolinska Institutet, Nobels väg 6, SE-171 77 Stockholm, Sweden.ORCID https://orcid.org/0000-0003-2377-436X
Cecilia LindeHeart Centre, Karolinska University Hospital, Eugeniavägen 3, SE-171 76 Stockholm, Sweden.ORCID https://orcid.org/0000-0002-9039-6023
Frieder BraunschweigHeart Centre, Karolinska University Hospital, Eugeniavägen 3, SE-171 76 Stockholm, Sweden.ORCID https://orcid.org/0000-0002-4966-1315

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: We compared the effects of 'ablate and pace' to pharmacological therapy on mortality and left ventricular ejection fraction (LVEF) in patients with atrial fibrillation (AF), with or without heart failure (HF). Methods and results: Articles were identified by searching PubMed, Central, and Embase until 30 June 2024. Inclusion criteria encompassed observational and randomized controlled trials (RCTs) comparing 'ablate and pace' with pharmacological therapy and investigating outcomes of mortality and LVEF in patients with AF. An exclusion criterion was lack of a parallel study design. The primary outcomes were all-cause mortality and the mean difference (MD) in LVEF. Endpoints were assessed through meta-analyses computing relative risks (RRs) and MDs. The clinical diagnosis of HF was used to distinguish between patients with and without HF. Initially, 3837 studies were identified, of which 24 ( Conclusion: 'Ablate and CRT' reduced mortality in HF patients as compared with pharmacological therapy, which was supported by statistical associations in observational studies. A single RCT corroborated the finding.

Indexed as

Ablate and paceAll-cause mortalityAtrial fibrillationHeart failureLeft ventricular ejection fractionMeta-analysis

Identifiers

PMID41835811
PMCPMC12988461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.